Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2002, Vol. 7 ›› Issue (6): 504-507.

Previous Articles     Next Articles

Randomized and contrast study on the combined effects of three antihypertensive drugs in the patients with subcortical arteriosclerotic encephalopaphy

CHEN Chun-Fu, CAO Bing-Zhen, SHEN Jun, CHANG Gao-Feng, SHANG Ming-Qian, CAO xia, JIN Shan, LU Wei   

  1. Department of Neurology,Jinan Military General Hospital,Jinan 250031
  • Received:2002-08-06 Revised:2002-08-28 Online:2002-12-26 Published:2020-11-20

Abstract: AIM: To compare the effects of three types of antihypertensive drugs of delayed-action preparation(DAP)and three types of typical preparation(TP)on the blood pressure of patients with subcortical arteriosclerotic encephalopaphy.METHODS: Sixty-six patients with subcortical arteriosclerotic encephalopaphy were randomly divided into DApgroupand Tpgroup,each groupincluding 33 patients.Three types of antihypertensive drugs of DApand TP,including calcium antagonist,β-receptor blocker and angiotensin converting enzyme inhibitor,were used orally in respective groupfor ten consecutive weeks.Blood pressure and heart ratewere monitored dynamically.Activities of daily living(ADL)of each patient were investigated before and after treatment.RESULTS: Total effective rates of antihypertension were 93.9% and 87.9% in DApgroupand in Tpgroup,respectively(p>0.05).The effects of DApwere found to be stable in day time and at night.The rates of side effects were 15.2% and 42.4%(p<0.05)in DApgroupand Tpgroup,respectively.Most side effects were mild and transient in DApgroup,without significant effect on the heart rate.There was not significant change on ADL scores in both groups after the treatment(p>0.05).CONCLUSION: Antihypertensive drugs of ADpare effective agents with a good tolerance in treatment of hypertensive patients with subcortical arteriosclerotic encephalopathy.

Key words: subcortical arteriosclerotic encephalopathy, blood pressure, calcium antagonist, β-receptor blocker, angiotensin converting enzyme inhibitor, delayed-action preparations

CLC Number: